Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Good early results for Noven/Shire ADHD patch
These trial results are expected to be included as part of an amendment to the new drug application for the methylphenidate transdermal system (MTS) product currently pending at
These trial results are expected to be included as part of an amendment to the new drug application for the methylphenidate transdermal system (MTS) product currently pending at
The phase II study results show that LymphoStat-B (belimumab) is safe and well tolerated, biologically active, and reduces the signs and symptoms of rheumatoid arthritis at a level
The trial met its primary endpoint of a greater proportion of Rituxan-treated patients achieving an American College of Rheumatology (ACR) 20 response at week 24, compared to placebo.
The decision to discontinue the clinical trials is based on the recommendations of two separate independent data and safety monitoring boards (DSMBs). The onercept (recombinant tumor necrosis factor
The study, published in the Journal of the American Medical Association (JAMA), represents one of the largest, most comprehensive clinical trials evaluating the use of medication for the
The study is being conducted under a cooperative R&D agreement (CRADA) between Cell Therapeutics Inc (CTI) and the US National Cancer Institute (NCI) and involves three of the
When finalized, the license will grant Protox exclusive worldwide rights to commercialize a genetically modified Aerolysin-antibody construct developed by the research institutions as a targeted therapy for the
According to research published in the Public Library of Science (PLoS) Medicine, a team from Imperial College London and Royal Brompton Hospital have discovered a way to decrease
In a presentation to financial analysts, company leaders say they will leverage the company’s competitive advantages to meet the challenges posed by patent expirations in the 2004-2007 period
The data show that administration of INGN 241 induces apoptosis (programmed cell death) in cancer cells but not in normal cells. Additionally, INGN 241 sensitizes tumors to conventional